Setmelanotide (IMCIVREE)

FDA-approved context Weight Loss & Metabolism 3 sources

Setmelanotide is an FDA-approved melanocortin-4 receptor (MC4R) agonist used for chronic weight management in individuals with specific rare genetic disorders of obesity. Research shows it effectively reduces hyperphagia (extreme hunger) and promotes significant weight loss by restoring function in the impaired MC4R pathway.

01Dosing reference

Amount

2-3 mg/day (adults)

Frequency

Once daily

Cycle

Continuous daily use as prescribed

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

MC4R Activation

Setmelanotide binds to and activates the melanocortin-4 receptor (MC4R) in the hypothalamus.

Appetite Regulation

Activation of MC4R signals the brain to reduce appetite and increase energy expenditure, counteracting hyperphagia.

Weight Reduction

The combined effect of reduced caloric intake and increased energy expenditure leads to significant weight loss in patients with specific genetic deficiencies.

03Human evidence

Significant weight loss in POMC and LEPR deficiency

Phase 3 clinical trials showed that a majority of patients with POMC or LEPR deficiency achieved at least 10% weight loss after one year of treatment.

Reduction in hyperphagia

Patients reported a substantial decrease in extreme hunger scores, significantly improving their quality of life and eating behaviors.

04Preclinical evidence

Restoration of MC4R signaling

In vitro studies demonstrated that setmelanotide acts as a potent agonist at the MC4R, restoring signaling pathways disrupted by genetic mutations.

Weight loss in obese animal models

Animal models with MC4R pathway defects showed reduced food intake and weight loss when treated with setmelanotide.

05What is known vs. unknown

Reasonably established

Setmelanotide is FDA-approved for obesity caused by POMC, PCSK1, or LEPR deficiency.
It works by agonizing the MC4R, a critical receptor in the brain's appetite regulation center.
Treatment leads to significant reductions in both body weight and hyperphagia.
It is administered via daily subcutaneous injection.

Unknowns & limits

Its efficacy in general obesity (without specific genetic mutations in the MC4R pathway) is limited and not approved.
Long-term cardiovascular safety and effects on psychiatric conditions require ongoing monitoring.

06Safety & regulatory context

Regulatory statusSetmelanotide (Imcivree) is FDA-approved for specific rare genetic obesities. Common side effects include injection site reactions, skin hyperpigmentation (due to cross-reactivity with MC1R), nausea, and headache. It carries warnings for spontaneous penile erections in males, sexual adverse reactions in females, depression, and suicidal ideation. It is not indicated for general obesity.

07Compared with Semaglutide

Setmelanotide (IMCIVREE) vs. Semaglutide

Key difference

Setmelanotide targets the MC4R pathway specifically for rare genetic obesities, whereas Semaglutide is a GLP-1 receptor agonist used for broader populations with obesity or type 2 diabetes.

When researchers discuss each

Researchers discuss Setmelanotide when addressing monogenic or syndromic obesity involving the melanocortin pathway, and Semaglutide for general metabolic syndrome and weight management.

08Glossary

MC4R

Melanocortin-4 receptor, a protein in the brain that plays a key role in regulating appetite and energy balance.

Hyperphagia

An abnormal, extreme, and insatiable desire for food, often seen in certain genetic obesity disorders.

POMC

Proopiomelanocortin, a precursor protein that is cleaved to form hormones involved in appetite regulation.

09Knowledge check

Q1What is the primary mechanism of action for Setmelanotide?

Q2Which of the following is a common side effect of Setmelanotide due to its mechanism?

Q3Based on the dossier, which statement best reflects a documented limitation of setmelanotide's clinical use?

Q4According to the dossier's stated comparison, in which research context are setmelanotide and semaglutide most appropriately discussed together?

Q5Which safety concern is explicitly listed in the dossier and would be a reason for monitoring patients on setmelanotide?

10Sources

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism

Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism

Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism

Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.